VIVEbiotech will be attending CAR-TCR Summit 2026

VIVEbiotech is attending the CAR-TCR Summit 2026 organized by Hanson Wade, taking place in Boston from September 15 to 17. Recognized as one of the key meeting points for companies and experts driving innovation in cell therapies, the event brings together leading stakeholders across the CAR-T and TCR landscape to discuss the latest scientific, manufacturing and regulatory developments shaping the future of the field.

Following its participation in Advanced Therapies Europe 2026, VIVEbiotech continues to strengthen its engagement with the global cell and gene therapy community, connecting with strategic partners and industry leaders to address the evolving challenges and opportunities in advanced therapy manufacturing.

During the summit, Peter Jähn will represent VIVEbiotech and be available to discuss how the company’s tailored lentiviral vector solutions support programs from early-stage development through clinical studies and commercial manufacturing. As demand for innovative CAR-T and TCR-based therapies continues to grow, reliable and scalable lentiviral vector manufacturing remains essential to advancing these therapies toward patients.

Throughout the event, VIVEbiotech will engage with attendees to explore how its expertise in lentiviral vector development and GMP manufacturing can help accelerate therapeutic programs while meeting the specific requirements of each project.

CAR-TCR Summit provides a valuable forum for collaboration, knowledge sharing and partnership development across the cell therapy ecosystem. VIVEbiotech looks forward to meeting industry peers and contributing to discussions that are helping drive the next generation of innovative cell and gene therapies.

Those interested in connecting with the VIVEbiotech team can schedule a meeting through the event platform or contact directly via our website.